Floatz logo

Epoetin Alfa

Stroke

Stem Cell Therapeutics Corp.Phase 2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
65/ 100

Competitive context

141 Active assets in the Stroke cohort.

Asset / SponsorPhaseRating
Rivaroxaban
China National Center for Cardiovascular Diseases
Phase 4BBB
Tenecteplase
Assistance Publique - Hôpitaux de Paris
Phase 4BBB
Acetylsalicylic Acid
China National Center for Cardiovascular Diseases
Phase 4BB
Ticagrelor
Assistance Publique - Hôpitaux de Paris
Phase 4BB
WARFARIN
China National Center for Cardiovascular Diseases
Phase 4BB

View all 50 →

Same molecule, other indications

Epoetin Alfa is also rated in:

anemiaDormant
BBB
Indicative ·
79 / 100
View asset →
plasma cell myelomaDormant
BB
Indicative ·
71 / 100
View asset →
precancerous conditionDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →